The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

A potential rally to 6,000 is possible if retail sales are positive and the FOMC Meeting is dovish. Read why investors should ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8528 ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...